Our top pick for
Tilray, Inc is a drug manufacturers-specialty & generic business based in the US. Tilray shares (TLRY) are listed on the NASDAQ and all prices are listed in US Dollars. Tilray employs 1,030 staff and has a trailing 12-month revenue of around USD$191.3 million.
|Latest market close||USD$24.5|
|52-week range||USD$2.43 - USD$55.01|
|50-day moving average||USD$25.0864|
|200-day moving average||USD$11.4535|
|Wall St. target price||USD$19.32|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-02-23)||N/A|
|1 month (2021-02-02)||N/A|
|3 months (2020-12-02)||N/A|
|6 months (2020-09-02)||N/A|
|1 year (2020-03-02)||N/A|
|2 years (2019-03-02)||N/A|
|3 years (2018-03-02)||N/A|
|5 years (2016-03-02)||N/A|
|Revenue TTM||USD$191.3 million|
|Gross profit TTM||USD$25.2 million|
|Return on assets TTM||-8.76%|
|Return on equity TTM||-82.25%|
|Market capitalisation||USD$4.4 billion|
TTM: trailing 12 months
There are currently 27.7 million Tilray shares held short by investors – that's known as Tilray's "short interest". This figure is 10% down from 30.8 million last month.
There are a few different ways that this level of interest in shorting Tilray shares can be evaluated.
Tilray's "short interest ratio" (SIR) is the quantity of Tilray shares currently shorted divided by the average quantity of Tilray shares traded daily (recently around 62.9 million). Tilray's SIR currently stands at 0.44. In other words for every 100,000 Tilray shares traded daily on the market, roughly 440 shares are currently held short.
However Tilray's short interest can also be evaluated against the total number of Tilray shares, or, against the total number of tradable Tilray shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tilray's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 Tilray shares in existence, roughly 170 shares are currently held short) or 0.1838% of the tradable shares (for every 100,000 tradable Tilray shares, roughly 184 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tilray.
Find out more about how you can short Tilray stock.
We're not expecting Tilray to pay a dividend over the next 12 months.
Over the last 12 months, Tilray's shares have ranged in value from as little as $2.43 up to $55.01. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tilray's is 2.8296. This would suggest that Tilray's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, clinics, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, Germany, Israel, New Zealand, Portugal, Spain, Africa, Switzerland, the United States, Malta, and the United Kingdom. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.